The positive results from the phase 3 CheckMate76K trial suggest that recurrence-free survival may be improved following treatment with adjuvant nivolumab vs placebo in fully resected stage IIB/C melanoma.
Russ Conroy
Advertisement
Russ Conroy is an Associate Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022.
On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.
Articles by Russ Conroy
Findings from a phase 2 clinical study indicated that neoadjuvant pegylated liposomal doxorubicin plus cyclophosphamide, trastuzumab, and pertuzumab demonstrated promising efficacy and safety in the treatment of HER2-positive breast cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
2
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
3
PFS Continues to Improve With Imlunestrant in Advanced Breast Cancer
4
QOL Improvement in Breast Cancer Noted With YES System
5
